Date:	3/21/2022
Your Name:	Oliver Rivero-Arias
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	This project was funded by the National Institute for Health Research (UK): Health Technology Assessment Programme (NIHR127489).	Payment to the University of Oxford for my time as PI and full cost of grant  Click the tab key to add additional rows.
		Time frame: past 36 month	ns .
2	Grants or contracts from any entity (if not indicated in item	None  NIHR HTA Grant: Treating Oesophageal Atresia to prevent STricture (TOAST) (NIHR131136)	Payment to University of Oxford for my time
	#1 above).	NIHR HTA Grant: Multicentre open label, pragmatic randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress (NIHR17/89/07)  NIHR HTA Grant: FROSTTIE: A randomised controlled trial of FRenotomy and breastfeeding support Or breastfeeding Support without frenotomy to investigate continuation of breastfeeding for babies with Tongue-TIE (NIHR16/143/01)	Payment to University of Oxford for my time as Co-I  Payment to University of Oxford for my time as Co-I

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		NIHR HTA Grant: Investigating the clinical and cost-effectiveness of a nutrient enriched diet for babies with a brain injury: The Dolphin Randomised controlled trial (NIHR130925)	Payment to University of Oxford for my time as Co-I
		NIHR HTA Grant: Pregnancy AntihyperteNsive Drugs: which Agent is best? (giant PANDA study) (NIHR128721)	Payment to University of Oxford for my time as Co-I
		NIHR Programme Grant: Improving unwarranted variation in outcomes of children's surgery through a new Children's Surgery Outcome Reporting system using routinely available data (CSOR) (NIHR127844)	Payment to University of Oxford for my time as Co-I
		NIHR HTA Grant: Clinical and/or cost-effectiveness of first trimester ultrasound screening for fetal anomalies: Is a prospective study an efficient investment? (NIHR 17/19/10)	Payment to University of Oxford for my time as Co-I
		NIHR HTA Grant: The neoGASTRIC trial: Avoiding routine gastric residual volume measurement in neonatal critical care, a multi-centre, randomised controlled trial (NIHR134216)	Payment to University of Oxford for my time as Co-I
		NIHR Invention for Innovation Grant: Decision- support for individualised risk assessment of fetal health during labour: preventing fetal brain damage and death by utilising large, routinely collected datasets of cardiotocography and clinical risk factors (NIHR202117)	Payment to University of Oxford for my time as Co-I
		NIHR Programme Grant: The 'PANDA' research programme: Primary prevention of maternal ANaemia to avoid preterm Delivery and other Adverse outcomes (NIHR200869)	Payment to University of Oxford for my time as Co-I
		NIHR Programme Grant: Optimising the management of blood pressure following hypertensive pregnancy to reduce cardiovascular risk (NIHR203283)	Payment to University of Oxford for my time as Co-I
3	Royalties or licenses	□ None	
4	Consulting fees	□ None	
5	Payment or honoraria for	□ None	
	lectures, presentations, speakers		
	,	12/12/2021	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	bureaus, manuscript writing or educational events		
6	Payment for expert testimony	□ None	
7	Support for attending meetings and/or travel	□ None	
8	Patents planned, issued or pending	□ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Independent panel member of the UK National Screening Committee Fetal and Maternal Child Health Reference Group  Panel member of the NIHR Doctoral Research Fellowships	Unpaid Unpaid
11	Stock or stock options	□ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
13	Other financial or non-financial interests	None    report I am a cofounding partner and shareholder of Maths in Health, a health	Paid
		economics and outcomes research consultancy company.	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	3/21/2022
Your Name:	May Ee Png
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month:	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	4/6/2022
Your Name:	Ashley L White
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/23/2022
Your Name:	Miaoqing Yang
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	for the (e.g., ovision aterials, iting, esssing c.)  None    None		
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	□ None	
	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/7/2022	
Your Name:	Sian Taylor-Phillips	
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)	
Manuscript Number (if known):	HTA NIHR127489	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily		

indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning	of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIHR CDF-2016-09-018 – Research Fellowship NIHR Warwick Evidence	Funding to institution for this work Funding to institution for this work Funding to institution for this work  Funding to institution for this work
	Time frame: past 36 month	ıs
Grants or contracts from any entity (if not indicated in item #1 above).	My institution receives grant funding from the National Institute for Health and Care Excellence (NICE) and the UK National Screening Committee for evidence synthesis and economic modelling work.	Funding to institution for this work

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None     Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid	member of the UK NSC Adult Reference Group and supported by an NIHR Career Development Fellowship (CDF-2016-09-018).  UK National Screening Committee Research and Methodology Sub-Group, Chair, May 2022-present  UK National Screening Committee, Data Scientist Member, May 2022-present  UK National Screening Committee Artificial Intelligence Task Group Member  National Breast Cancer Screening Clinical Advisory Group, member 2019-present  SPIE Medical Imaging Society, committee member (2016-present) and conference chair (2020-2022), Image Perception, Observer Performance, and Technology Assessment	No payments for NSC membership but payments made to the University of Warwick to support Sian's salary by her NIHR fellowship Unpaid	
11	Stock or stock options	⊠  None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

3/29/2022

Date:

re related to the e interests may be ot necessarily you do so.  ertains to the nedication, even if
e interests may be of necessarily you do so. ertains to the nedication, even if
e interests may be of necessarily you do so. ertains to the nedication, even if
redication, even if
.g., if payments were
tution)
WS.

NIHR127844 2020-2025

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Exploring the potential for using mother's experiences of pre-term birth to improve care in LMICs. UKRI t: MR/T017759/1 2020-2023	Principal investigator
3	Royalties or licenses	None None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety	[□] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Monitoring Board or Advisory Board	NIHR HS & DR Associate Board from 16/06/2014 to 30/06/2018.	Associate board member	
	,	NIHR Programme Grants for Applied Research 2018-2022	Board member	
		ICNARC 2009-2022	Board of Trustees	
		Global Institute for Global Health 2019-2023	Honorary Senior Fellow	
		Royal College of Obstetricians and Gynaecologists, Race Equality Taskforce	Member	
10	Leadership or fiduciary role in other board, society, committee or	[⊠] None		
	advocacy group, paid or unpaid			
11	Stock or stock options	⊠  None		
12	Receipt of equipment, materials, drugs,	[⊠] None		
	medical writing, gifts or other			
	services			
13	Other financial or non-financial	[⊠] None		
	interests			
Plea	Please place an "X" next to the following statement to indicate your agreement:			
	$oxed{oxed}$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

3 12/13/2021 ICMJE Disclosure Form

Date:	3/23/2022
Your Name:	Felicity Boardman
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIHR Health Technology Assessment Programme, 2019 (£530, 013.53) REF: NIHR 127489 (5%). The benefits and harms of antenatal and newborn screening programmes in health economic assessments, the VALENTIA study	Click the tab key to add additional rows.
	tins item.	Time for seed 20 months	
2	Grants or contracts from any entity (if not indicated in item	None  NIHR October 2021- November 2022 Testing the	Payment for 5% of my time paid to institution
	#1 above).	acceptability of EarLy Surveillance for Autoimmune diabetes: The ELSA Study Ref: NIHR202816 (5% costing) Public Health England, 2021-2022 (£98,690.86), (10%) Evaluation of Next Generation Sequencing for Cystic Fibrosis Newborn Screening. Ref: NHS	Payment for 10% of my time paid to institution
		England and NHS Improvement (NHSE/I) 50047HO Wellcome Trust Small Grant in Humanities and Social Science, 'Developing future research agendas on the socioethical impact of genomics	Paid to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		through interdisciplinary live data-sharing', Sept 2021-Sept-2023. (£35, 437). Ref: 219426/Z/19/Z Wellcome Trust Investigator Award, February 2017- January 2022 (£248, 802) Ref: 203384/Z/16/Z	Paid to Institution
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety	⊠  None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Commer made to you or to your	nts (e.g., if payments were institution)
	Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Member of Foetal Maternal and Child Health Reference Group, National Screening Committee	
11	Stock or stock options	Image: square of the square o	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	se place an "X" nex	xt to the following statement to indicate your agreement:	
	I certify that I have	e answered every question and have not altered the wording of any of the questi	ons on this form.

3 12/13/2021 ICMJE Disclosure Form

Date:	3/31/2022
Your Name:	Abigail McNiven
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			<u></u>
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	[□] None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The funder of the study: HTA Project: NIHR127489 - Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments	Payment to University of Oxford.  Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None  NIHR Policy Research Programme: NIHR202450 - A qualitative study of people's experiences of urogynaecology health services in the UK Oliver Bird Fund, Nuffield Foundation: OBF/43985 - Understanding and improving decision making for joint replacement surgery in older patients with other complex health needs	Payment to University of Oxford.  Payment to University of Oxford.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None     Non	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None     ■	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None     Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠  None	
Plea [⊠]		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Dat	e:	_	7/5/2022		
Your Name:		_	Jane Fisher		
Manuscript Title:		_	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)		
Maı	nuscript Number (if I	known):	Click or tap here to enter text.		
con affe indi	tent of your manuscr cted by the content cate a bias. If you ar	ript. "Relat of the man e in doubt	ted" means any relation with for-profit or in uscript. Disclosure represents a commitme about whether to list a relationship/activition.		
epic	•	ension, you	should declare all relationships with manu	example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
	em #1 below, report ne for disclosure is th			without time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	g of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		applicant my charity (Antenatal Results ices) has received funds from the	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	As a co-a	applicant my charity (Antenatal Results ices) has received funds from the	Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	As a co-a	applicant my charity (Antenatal Results ices) has received funds from the IA study  Time frame: past 36 montaine	Click the tab key to add additional rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	As a co-a and Cho VALENTI	applicant my charity (Antenatal Results ices) has received funds from the IA study  Time frame: past 36 montine	Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	□ None	
7	Support for attending meetings and/or travel	□ None	
8	Patents planned, issued or pending	□ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Member of UK National Screening Committee (until June 2022)  Member of UKNSC Fetal Maternal and Child Helath Reference Group  Member of NHS England Fetal Anomaly Screening Programme Advisory Group	No payment  No payment  No payment

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None	
13	Other financial or non-financial interests	None	
	•	to the following statement to indicate your agreeme	
$[\boxtimes]$	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.

Date:	3/21/2022
Your Name:	Professor Baskaran THILAGANATHAN
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIHR HTA Reference Number: NIHR127489 - Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments  Time frame: past 36 month	2.5 % FTE paid to St George's University Hospitals Foundation NHS Trust in lieu of my involvement in support of the study  Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Funding from Tommy's Charity for the National Centre for Maternity Improvement based at the RCOG and RCM	10 % FTE paid to St George's University Hospitals Foundation NHS Trust in lieu of my involvement in support of the study
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	Member of the Fetal, Maternal and Child Health reference group of the UK NSC  Clinical lead for the SAFE test (NIPT) laboratory at St Georges Hospital (www.theSAFEtest.co.uk)	No pecuniary interests in either service
Please place an "X" next to the following statement to indicate your agreement:  \[ \begin{align*} \Boxed{I} \text{ certify that I have answered every question and have not altered the wording of any of the questions on this form.} \end{align*}			

Date:	4/1/2022
Your Name:	Sam Oddie
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	NIHR HTA Reference Number: NIHR127489 - Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments  Time frame: past 36 months	Funding received as part of grant that produced the report  Click the tab key to add additional rows.
3	Royalties or licenses	None □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Serves on the UK NSC expert group on implementing saturation screening.	Unpaid advisory role

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Your Name:

Manuscript Title:

Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)

Manuscript Number (if known):

Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Institute for Health Research	payment to the University of Warwick for my time
	medical writing, article processing charges, etc.) No time limit for this item.		Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	Grant funding from NIHR HS&DR programme for study Evaluating ReSPECT in primary care	Payment to University of Warwick for my time as CI and full cost of grant
	#1 above).	(13/13/16) Grant funding from NIHR HS&DR programme for study Evaluation of emergency care and treatment plans (15/15/09)	Payment to University of Warwick for my time as Co-I
		Grant funding from NIHR HS&DR programme for study Exploring and improving resuscitation decisions in out of hospital cardiac arrest (17/99/34)	Payment to University of Warwick for my time as Co-I
		Grant funding from NIHR HTA programme for study PARAMEDIC 3 (13/11/05)	Payment to University of Warwick for my time as Co-I

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Grant funding from NIHR HTA programme for study Induction of labour for predicted macrosomia (The 'Big Baby Trial') (16/77/02)	Payment to University of Warwick for my time as Co-I
3	Royalties or licenses	□ None	
4	Consulting fees	□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	□ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	□ None	
9	Participation on a Data Safety	□ None	

Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options    Monitoring Board or Advisory Board    Image: Advisory Board		
fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock  fiduciary role in other board, society, Clinical Ethics Network  Trustee of UK Clinical Ethics Network  Unpaid  Trustee of UK Clinical Ethics Network  Unpaid  Trustee of UK National Screening Committee  Unpaid  None		
Receipt of equipment, materials, drugs, medical writing, gifts or other services		
Other financial or non-financial interests  None		
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

3 12/13/2021 ICMJE Disclosure Form

Date:	4/7/2022
Your Name:	Svetlana Ratushnyak
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.	
		Time frame: past 36 months	S	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None		
3	Royalties or licenses	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	4/5/2022
Your Name:	Nia Wyn Roberts
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	ript (e.g., provision materials, writing, rocessing etc.)  limit for		Click the tab key to add additional rows.
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/21/2022
Your Name:	Jenny Shilton Osborne
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	3/21/2022
Your Name:	Stavros Petrou
Manuscript Title:	Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	This project was funded by the National Institute for Health Research (UK): Health Technology Assessment Programme (NIHR127489).	Click the tab key to add additional rows.
		Time frame: past 36 month:	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Financial support provided by NIHR Senior Investigator Ref NF-SI-0616-10103 award; 'Cross-Cultural Adaptation of the Beta EQ-5D-Y-5L Into Chichewa (Malawi)'  Financial support provided by the NIHR Applied Research Collaboration Oxford and Thames Valley.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	Image: square of the property o	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	□ None	

,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
society, committee or advocacy group, paid or unpaid	(1) Member of the NIHR Programme Grants for Applied Research "PERFORM study (Personalised Exercise-Rehabilitation for people with Multiple long-term conditions)"	
	Study Steering Committee (2021-).  (2) Member of the NIHR Health Technology Assessment Programme "Cluster Randomised Controlled Trial of a Service to Support the Mental Health and Coping of Parents with Excessively Crying Infants" Trial Steering Committee (2021-).	
	(3) Member of the NIHR Pre-Doctoral Fellowship Assessment Panel (2019- ).	
	(4) Member of the NIHR Health Technology Assessment Programme "Patient-reported outcome measures for monitoring primary care patients with depression: PROMDEP randomised controlled trial" Trial Steering Committee (2018-).	
	(5) Member of the NIHR Public Health Research Programme "Does 'Mellow Babies' improve the psychosocial health of mothers and their children? The Mellow Babies Trial" Trial Steering Committee (2018-).	
	(6) Member of the NIHR Health Services and Delivery Research "Critically ill children and young people: do national Differences in access to Emergency Paediatric Intensive Care and care during Transport affect clinical outcomes and patient experience? The DEPICT study" Study Steering Committee (2017-).	
	(7) Member of the NIHR Health Technology Assessment Programme "Nail Bed Injury Analysis (NINJA)" Trial Steering Committee	
	(2017-2021).  (8) Member of the NIHR Health Services and Delivery Research "Opti-Prem: Optimising neonatal service provision for preterm babies born between 27 and 31 weeks of gestation in England, using national data, qualitative research and economic analysis" Study Steering Committee (2017-).	
	(9) Member of the NIHR Public Health Research Programme 'The Best Services Trial (BeST): Effectiveness and cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health' Trial Steering Committee (2015-).	
	Deputy Directory, Oxford and Thames Valley Applied Research Collaboration (ARC) (2022-)	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			